Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234469 | 0.79 | SRD5A1 (0.40) | ALDH1A1GABRG2GABRB3GABRA5CYP2C19 | |
| SCHEMBL2238527 | 0.74 | NOTUM (0.38) | ALDH1A1GABRG2GABRB3GABRA5HIF1A | |
| SCHEMBL2232968 | 0.73 | KDM4E (0.31) | KDM4E | |
| SCHEMBL2238273 | 0.73 | SMN1; SMN2 (0.39) | L3MBTL1ALDH1A1KDM4ENPC1GAA | |
| SCHEMBL2234061 | 0.72 | HTR2A (0.32) | — | |
| SCHEMBL2234684 | 0.71 | GABRG2 (0.55) | GABRG2GABRB3GABRA5 | |
| SCHEMBL9077783 | 0.71 | BRPF1 (0.36) | L3MBTL1ALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL2234693 | 0.68 | GABRG2 (0.54) | L3MBTL1ALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL2234063 | 0.65 | KCNJ1 (0.33) | ALDH1A1GABRG2GABRB3GABRA5KDM4E | |
| SCHEMBL2234603 | 0.64 | GABRG2 (0.34) | ALDH1A1GABRG2GABRB3GABRA5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | L3MBTL1 2487/4885ALDH1A1 4182/4885GABRG2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.